Liquidia Corporation
LQDADrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Aug 11, 2026
4wMarket Overview
Stock performance and key metrics
2 upcoming, 1 past
How LQDA's past catalysts played out
LIQ861 Inhaled Treprostinil
Primary Pulmonary Hypertension
L606
Pulmonary Hypertension Due to Lung Disease (Disorder)
Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)
Influenza
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
LIQ861 Inhaled Treprostinil | Phase 3 | Primary Pulmonary Hypertension | - | - |
L606 | Phase 3 | Pulmonary Hypertension Due to Lung Disease (Disorder) | - | - |
Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) | Phase 2 | Influenza | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Liquidia Corporation's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Liquidia Corporation's (LQDA) pipeline across Phase 3, Phase 2. Its lead program is LIQ861 Inhaled Treprostinil (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Liquidia Corporation's next FDA catalyst?→
Liquidia Corporation's (LQDA) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LQDA biotech catalysts?→
Add LQDA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Liquidia Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.